Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Simcere Pharmaceutical

- PMLiVE

Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

- PMLiVE

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

- PMLiVE

Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies

The companies will work together to develop new therapies to re-establish immune tolerance and repair tissue for those with inflammatory bowel diseases

- PMLiVE

BMS and 2seventy bio announce positive results for multiple myeloma treatment

The results show that Abecma ‘significantly improves’ progression-free survival in relapsed and refractory multiple myeloma

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Bristol Myers Squibb launches initiative to ensure disability diversity in clinical trials

Current common clinical trial practices exclude up to a quarter of the US population based on disability status

- PMLiVE

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Bristol Myers Squibb announces positive trial results for treatment of MS

In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

- PMLiVE

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program

The $100m initiative was started in 2020 to increase diversity in clinical trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links